{"id":33592,"date":"2025-05-16T12:40:11","date_gmt":"2025-05-16T04:40:11","guid":{"rendered":"https:\/\/flcube.com\/?p=33592"},"modified":"2025-05-16T12:40:12","modified_gmt":"2025-05-16T04:40:12","slug":"merck-kgaa-reports-q1-2025-financials-with-2-5-organic-sales-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33592","title":{"rendered":"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Merck KGaA (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:ETR\">ETR: MRK<\/a>) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY) increase in group net sales on an organic basis, reaching EUR 5.3 billion (USD 5.9 billion) over the three-month period. The Healthcare segment led the growth with a 3.4% organic increase in net sales to EUR 2.1 billion (USD 2.4 billion), while EBITDA pre rose by 11.7% to EUR 796 million (USD 892 million), primarily due to temporarily reduced R&amp;D expenditure. The Cardiovascular, Metabolism and Endocrinology franchise was the main driver, with organic growth across all therapeutic areas, increasing net sales by 10.6% to EUR 757 million (USD 848 million).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Therapeutic Area Performance<\/strong><br>In the Oncology business, revenue reached EUR 491 million (USD 550 million), showing a 1.9% decline. Erbitux (cetuximab) sales grew by 6.2% to EUR 305 million (USD 342 million), while Bavencio (avelumab) sales decreased by 15.4% to EUR 157 million (USD 176 million). The Neurology &amp; Immunology business reported revenue of EUR 407 million (USD 456 million), a 3.7% decrease, with Mavenclad (cladribine) sales increasing by 9.2% to EUR 287 million (USD 321 million) and Rebif (recombinant human interferon \u03b21a) sales dropping by 25.1% to EUR 120 million (USD 134 million). Fertility therapies generated EUR 382 million (USD 428 million), with Gonal-F (recombinant human follitropin alfa) sales at EUR 206 million (USD 231 million, +0.3%) and Pergoveris (follitropin alfa\/lutropin alfa) sales at EUR 78 million (USD 87 million, +13.6%).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cardiovascular, Metabolism &amp; Endocrinology Segment<\/strong><br>The Cardiovascular, Metabolism &amp; Endocrinology segment reported strong growth of 10.6% to EUR 757 million (USD 845 million). Key contributors included Glucophage (metformin) sales of EUR 242 million (USD 271 million, +10.4%), Concor (bisoprolol) sales of EUR 157 million (USD 176 million, +12.2%), Euthyrox (levothyroxine) sales of EUR 155 million (USD 174 million, +12.7%), and Saizen (somatropin) sales of EUR 103 million (USD 115 million, +18.6%).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Full-Year Guidance and Tariff Update<\/strong><br>Merck made minor adjustments to its full-year 2025 guidance, forecasting revenue of EUR 20.9-22.4 billion, representing organic growth of 2%-6%. The Healthcare sector is projected to generate EUR 8.3-8.9 billion in revenue, with organic growth of 2%-6%. In response to tariff uncertainties, Merck announced a temporary surcharge for Life Science product orders shipped to China, effective May 12; however, this surcharge was halted one day later.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025-Q1-Earnings-Presentation-EN.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025-Q1-Earnings-Presentation-EN.\"><\/object><a id=\"wp-block-file--media-99da43fb-d53f-4a1a-b200-aad16a1248e8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025-Q1-Earnings-Presentation-EN.pdf\">2025-Q1-Earnings-Presentation-EN<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025-Q1-Earnings-Presentation-EN.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-99da43fb-d53f-4a1a-b200-aad16a1248e8\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025-Q1-Report-EN.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025-Q1-Report-EN.\"><\/object><a id=\"wp-block-file--media-e12d7244-0b0a-49b0-8205-730ad3c00b0c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025-Q1-Report-EN.pdf\">2025-Q1-Report-EN<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025-Q1-Report-EN.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e12d7244-0b0a-49b0-8205-730ad3c00b0c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33596,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27],"class_list":["post-33592","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY) increase in group net sales on an organic basis, reaching EUR 5.3 billion (USD 5.9 billion) over the three-month period. The Healthcare segment led the growth with a 3.4% organic increase in net sales to EUR 2.1 billion (USD 2.4 billion), while EBITDA pre rose by 11.7% to EUR 796 million (USD 892 million), primarily due to temporarily reduced R&amp;D expenditure. The Cardiovascular, Metabolism and Endocrinology franchise was the main driver, with organic growth across all therapeutic areas, increasing net sales by 10.6% to EUR 757 million (USD 848 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33592\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth\" \/>\n<meta property=\"og:description\" content=\"Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY) increase in group net sales on an organic basis, reaching EUR 5.3 billion (USD 5.9 billion) over the three-month period. The Healthcare segment led the growth with a 3.4% organic increase in net sales to EUR 2.1 billion (USD 2.4 billion), while EBITDA pre rose by 11.7% to EUR 796 million (USD 892 million), primarily due to temporarily reduced R&amp;D expenditure. The Cardiovascular, Metabolism and Endocrinology franchise was the main driver, with organic growth across all therapeutic areas, increasing net sales by 10.6% to EUR 757 million (USD 848 million).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33592\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-16T04:40:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-16T04:40:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1607.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth\",\"datePublished\":\"2025-05-16T04:40:11+00:00\",\"dateModified\":\"2025-05-16T04:40:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1607.webp\",\"keywords\":[\"Finanical Reports\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33592#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33592\",\"name\":\"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1607.webp\",\"datePublished\":\"2025-05-16T04:40:11+00:00\",\"dateModified\":\"2025-05-16T04:40:12+00:00\",\"description\":\"Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY) increase in group net sales on an organic basis, reaching EUR 5.3 billion (USD 5.9 billion) over the three-month period. The Healthcare segment led the growth with a 3.4% organic increase in net sales to EUR 2.1 billion (USD 2.4 billion), while EBITDA pre rose by 11.7% to EUR 796 million (USD 892 million), primarily due to temporarily reduced R&D expenditure. The Cardiovascular, Metabolism and Endocrinology franchise was the main driver, with organic growth across all therapeutic areas, increasing net sales by 10.6% to EUR 757 million (USD 848 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33592\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1607.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1607.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33592#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth - Insight, China&#039;s Pharmaceutical Industry","description":"Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY) increase in group net sales on an organic basis, reaching EUR 5.3 billion (USD 5.9 billion) over the three-month period. The Healthcare segment led the growth with a 3.4% organic increase in net sales to EUR 2.1 billion (USD 2.4 billion), while EBITDA pre rose by 11.7% to EUR 796 million (USD 892 million), primarily due to temporarily reduced R&D expenditure. The Cardiovascular, Metabolism and Endocrinology franchise was the main driver, with organic growth across all therapeutic areas, increasing net sales by 10.6% to EUR 757 million (USD 848 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33592","og_locale":"en_US","og_type":"article","og_title":"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth","og_description":"Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY) increase in group net sales on an organic basis, reaching EUR 5.3 billion (USD 5.9 billion) over the three-month period. The Healthcare segment led the growth with a 3.4% organic increase in net sales to EUR 2.1 billion (USD 2.4 billion), while EBITDA pre rose by 11.7% to EUR 796 million (USD 892 million), primarily due to temporarily reduced R&D expenditure. The Cardiovascular, Metabolism and Endocrinology franchise was the main driver, with organic growth across all therapeutic areas, increasing net sales by 10.6% to EUR 757 million (USD 848 million).","og_url":"https:\/\/flcube.com\/?p=33592","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-16T04:40:11+00:00","article_modified_time":"2025-05-16T04:40:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1607.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33592#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33592"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth","datePublished":"2025-05-16T04:40:11+00:00","dateModified":"2025-05-16T04:40:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33592"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33592#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1607.webp","keywords":["Finanical Reports"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33592#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33592","url":"https:\/\/flcube.com\/?p=33592","name":"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33592#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33592#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1607.webp","datePublished":"2025-05-16T04:40:11+00:00","dateModified":"2025-05-16T04:40:12+00:00","description":"Merck KGaA (ETR: MRK) released its Q1 2025 financial results, reporting a 2.5% year-on-year (YOY) increase in group net sales on an organic basis, reaching EUR 5.3 billion (USD 5.9 billion) over the three-month period. The Healthcare segment led the growth with a 3.4% organic increase in net sales to EUR 2.1 billion (USD 2.4 billion), while EBITDA pre rose by 11.7% to EUR 796 million (USD 892 million), primarily due to temporarily reduced R&D expenditure. The Cardiovascular, Metabolism and Endocrinology franchise was the main driver, with organic growth across all therapeutic areas, increasing net sales by 10.6% to EUR 757 million (USD 848 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33592#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33592"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33592#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1607.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1607.webp","width":1080,"height":608,"caption":"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33592#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck KGaA Reports Q1 2025 Financials with 2.5% Organic Sales Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1607.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33592"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33592\/revisions"}],"predecessor-version":[{"id":33597,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33592\/revisions\/33597"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33596"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}